<DOC>
	<DOC>NCT01982539</DOC>
	<brief_summary>As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.</brief_summary>
	<brief_title>Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute</brief_title>
	<detailed_description>Open-label study, subjects will be dosed with Zipsor® for the treatment of mild to moderate acute pain for up to 4 days.</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Male and female subjects between 1217 years of age. Subjects must be postop, having mild or moderate acute pain. Other inclusions apply. Subject has a known history of allergic reaction, hypersensitivity to diclofenac, aspirin, acetaminophen, or reaction to the nonactive ingredients of the study medication. Subject has been taking analgesic for 4872 hours prior to Screening. Subject has a history of any GI event greater than 6 months before Screening. Subject is currently receiving any medication that is contraindicated for use concomitantly with diclofenac or acetaminophen. Subject has previously participated in another clinical study of Zipsor or taking Zipsor for any other indication. Subject is requiring treatment for preexisting hypertension. Other exclusions apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>pain</keyword>
	<keyword>NSAID</keyword>
	<keyword>moderate pain</keyword>
	<keyword>mild pain</keyword>
	<keyword>acute pain</keyword>
	<keyword>mild acute pain</keyword>
	<keyword>moderate acute pain</keyword>
	<keyword>mild or moderate acute pain</keyword>
</DOC>